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To the Editor: 
Chronic airway inflammation in asthmatic patients is classically biased toward TH2-type immunity, with 
IL-4 and IL-13 as signature cytokines initiating B-cell class-switching to IgE. Immunoglobulin class-
switching classically occurs in the lymphoid germinal centers, with B cells migrating in the tissue 
through the bloodstream. Demonstration of class-switching toward IgE by mucosal resident B cells has 
been provided in patients with allergic asthma and rhinitis. It is increasingly recognized that this local 
IgE synthesis can occur independently of systemic IgE sensitization, which is referred to as "atopy" 
and evidenced by positive serum IgE measurements, skin prick test responses, or both to at least 1 
common aeroallergen. Both the precise origin of IgE-positive B cells
1
 and the detailed specificities of 
local IgE remain elusive, but studies in allergic rhinitis and conjunctivitis reported that part of this local 
IgE might bind to aeroallergens, such as pollens.
2
 Our group also reported that functional IgE 
antibodies to house dust mite (Dermatophagoides pteronyssinus) allergens are detected in sputum 
from patients with nonatopic asthma.
3
 Similarly, D pteronyssinus-specific IgE was reported to be 
functional in nasal polyp tissues from nonatopic donors.
4
 The clinical relevance of local specific IgE 




In the present study we sought to evaluate sputum IgE antibodies to D pteronyssinus in a larger series 
of asthmatic patients and to correlate this local response to TH2/eosinophilic inflammation and notably 
to periostin, which was recently identified as a surrogate serum marker of airway eosinophilia in 
asthmatic patients. We hypothesized that the local production of allergen-specific IgE antibodies is 
promoted by IL-13 both in patients with allergic and those with nonatopic forms of asthma. 
Study participants (n = 149), including asthmatic patients and healthy control subjects, were assessed 
for the presence of D pteronyssinus-specific IgE in induced sputum. Asthmatic patients were 
extensively characterized for lung function, blood and sputum eosinophil counts, and serum IgE levels 
(see Table E1 in this article's Online Repository at www.jacionline.org) and consented to participate in 
the study approved by the local ethics committee (reference 2005/181). Induced sputum was obtained 
for each participant by means of inhalation of saline solution (4.5%; detailed methods for processing 
are provided in the Methods section in this article's Online Repository at www. jacionline.org). Sputum 
supernatants were assayed for D pteronyssinus-specific IgE by using ELISA, as previously described. 
Supernatants were also assessed for periostin. The assumption that periostin could be detected in the 
sputum is based on the in vitro observation that human primary bronchoepithelial cells cultured 
markedly upregulate periostin gene expression on IL-13 stimulation.
6
 We also observed that 
production of periostin occurs in air-liquid interface bronchoepithelial cultures in the basolateral and 
apical compartments, with the effect of IL-13 being significant only at the apical pole (Fig 2). 
It was first confirmed that D pteronyssinus-specific IgE is detectable in sputum at higher levels in 
asthmatic patients when compared with control subjects irrespective of atopy/systemic IgE 
sensitization (P < .05 and P < .001, patients with nonatopic and atopic asthma vs control subjects, 
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respectively; Fig 1, A), with 76% of patients with allergic asthma being sensitized to D pteronyssinus 
(serum D pteronyssinus-specific IgE >0.35 kU/L; see Table El). Sputum eosinophil counts were 
increased in both patients with atopic and those with nonatopic asthma as either absolute numbers or 
proportion of leukocytes (P < .001, nonatopic and atopic asthma vs control subjects), with no 
difference between the 2 asthmatic groups (Fig 1, B). Blood and sputum eosinophil counts were 
significantly correlated (r = 0.59, P < .001). Only a few patients from our series presented with blood 
eosinophil counts of 400/mm or greater and sputum eosinophil counts of 3% or greater (n = 9 [6.8%]), 
a profile that was previously associated with poor control of the disease.
7
 In sputum, despite levels 
being increased only in some asthmatic patients without reaching a significant between-group 
difference (Fig 1, C), periostin levels significantly correlated with D pteronyssinus-specific IgE levels (r 
= 0.37, P < .0001; Fig 1, D) but not eosinophil counts (r = 0.06; see Video E1 in this article's Online 
Repository at www.jacionline.org). No significant correlation was found between sputum periostin and 
sputum total IgE levels (r = 0.08, P = .43) or other asthma-related parameters. The absence of 
correlation between periostin levels and sputum eosinophil counts could be related to the large 






FIG 1. A. D pteronyssinus-specific IgE antibodies in sputum from patients with nonatopic (n = 34) or 
atopic (n = 77) asthma and sputum from nonatopic control subjects (n = 14). Lines depict medians and 
ranges. B, Sputum eosinophils (percentage of total leukocytes) from patients with nonatopic or atopic 
asthma versus nonatopic control subjects. Lines depict medians and ranges. Data were obtained from 
39 patients with intrinsic asthma, 89 patients with atopic asthma, and 21 control subjects. C. Periostin 
levels as assessed in DPBS sputum samples in patients with nonatopic (n = 33) and atopic (n = 79) 
asthma versus nonatopic control subjects (n = 21). Lines depict medians (interquartile ranges). D. 
Correlation between sputum levels of periostin and D pteronyssinus-specific IgE. Data were obtained 
for 114 of 149 subjects (r = 0.37, P < .0001), with 35 samples being lower than the detection limit (data 
not shown) for D pteronyssinus-specific IgE or periostin (0.75 ng/mL). *P< .05 and ***P< .001. 
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FIG 2. Periostin release (during culture for 48 hours) by human airway epithelial cells (AECs) on 
recombinant IL-13 stimulation (10 ng/mL every other day) versus control (medium alone) values in the 
basolateral and apical compartments, as assessed at weeks 2,3, and 4 in air-liquid conditions. Data 
are from AECs of 14 different donors. Lines depict medians (interquartile ranges). *P< .05. 
 
 
By using immunologic or molecular techniques, several studies demonstrated that local IgE production 
occurs in the upper and lower airways of patients with nonatopic rhinitis, nasal polyposis, and asthma. 
In contrast, the specificity of this local IgE was only recently explored.
2-4,9
 In the most recent report
10
 
the presence of local IgE was not confirmed in patients with nonatopic asthma by using a microarray 
analysis (Immuno-CAP ISAC; Thermo Scientific, Uppsala, Sweden) of bronchial biopsy homogenates. 
IgE antibodies to a large panel of allergens, including dust mite allergens, were not detected in these 
samples. The discrepancy between these results and ours could relate to methodological issues. The 
sensitivity of the microarray could be lower, as suggested by the detection of specific IgE in only a few 
patients with allergic asthma (in contrast to positive serum results), probably because of the described 
loss of total IgE after extraction and the assay characteristics, as the authors recognize. Another 
possibility relates to the site of sampling because it is uncertain whether tissue-bound IgE levels and 
secretory (sputum) IgE levels are correlated and could be affected by different local factors, including 
epithelial transport through the low-affinity receptor for IgE (CD23). Thus allergen-specific IgE 
responses should be clarified in patients with nonatopic asthma by assessing the different 
compartments of the bronchial mucosa, ideally by using different techniques, to detect the presence of 
local IgE antibodies. Of note, this study assayed fluid-phase (and not dithiothreitol-treated
4
) sputum 
samples, which could have affected the results by neglecting cell-bound IgE. In addition, the 
functionality and epitope repertoires should also be investigated and compared with those in serum 
because the clinical relevance of this mucosal response remains in question based on results of in 
vivo allergen challenge. Thus in contrast to patients with rhinitis, in whom one group observed clinical 
responses in some patients, no clinical reactivity was observed on lung challenge with mite allergen in 
patients with nonatopic asthma.
3
 
The present data show that periostin can be recovered in sputum consistently with the apical release 
of this protein observed in bronchoepithelial cell cultures at the air-liquid interface on stimulation by the 
TH2 cytokine IL-13. Periostin has been reported to be a novel serum biomarker of bronchial 
eosinophilic inflammation, which might be more reliable than exhaled nitric oxide. The correlation 
observed in the present study between sputum levels of periostin and D pteronyssinus-specific 
IgE antibodies, but not eosinophil counts, probably relates to their common triggering mechanism, 
namely the IL-4/IL-13 cytokine pathway. A recent study by Bobolea et al
8
 reports a significant 
correlation between sputum periostin levels and eosinophil counts. This discrepancy with our results 
might be explained by the study population, which focused on patients with severe refractory asthma. 
In any case, the interest in the sputum periostin level as an additional biomarker of asthma should be 
considered in further larger studies, notably to clarify the link between sputum levels of periostin and 
eosinophil counts. 
Our data confirm that in asthmatic patients local D pteronyssinus-specific IgE antibodies are 
detectable in sputum irrespective of atopy and show that this bronchial response correlates to the local 
periostin level as a marker of TH2-biased imprinting of the airway epithelium. 
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